Cullinan Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
08/11/2024 16:41
* Cullinan Therapeutics Inc CGEM.OQ reported a quarterly
adjusted loss of 69 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -91 cents. The mean expectation of
ten analysts for the quarter was for a loss of 81 cents per
share. Wall Street expected results to range from -99 cents
to -69 cents per share.
* Reported revenue was zero; analysts expected zero.
* Cullinan Therapeutics Inc's reported EPS for the quarter
was a
loss of 69 cents.
* The company reported a quarterly loss of $40.56 million.
* Cullinan Therapeutics Inc shares had fallen by 6.9% this
quarter and gained 52.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 3.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "buy."
Wall Street's median 12-month price target for Cullinan
Therapeutics Inc is 30.00
This summary was machine generated from LSEG data November 8 at
04:41 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.73 -0.69 Beat
Jun. 30 2024 -0.73 -0.75 Missed
Mar. 31 2024 -0.99 -0.86 Beat
Dec. 31 2023 -0.96 -0.54 Beat